{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:24:08Z","timestamp":1786983848232,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.abd.2025.501210","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:39:30Z","timestamp":1760798370000},"page":"501210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of nemolizumab in prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8714-2962","authenticated-orcid":false,"given":"Ana Carolina Putini","family":"Vieira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3194-1549","authenticated-orcid":false,"given":"Maria Ant\u00f4nia Costa","family":"Cruz Akabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7620-2119","authenticated-orcid":false,"given":"Gianna Carolinne Graff","family":"Caletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1434-1872","authenticated-orcid":false,"given":"K\u00e9len Klein","family":"Heffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5875-0240","authenticated-orcid":false,"given":"Amanda","family":"Tauana Oliveira e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2025.501210_bib0005","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2025.501210_bib0010","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","article-title":"Prurigo nodularis: epidemiology and clinical features","volume":"83","author":"Huang","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501210_bib0015","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.40677","article-title":"Depression, anxiety and suicidal ideation in prurigo nodularis: a systematic review and meta-analysis","volume":"104","author":"Jiang","year":"2024","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.abd.2025.501210_bib0020","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: pathogenesis and management","volume":"83","author":"Williams","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501210_bib0025","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s13555-022-00782-2","article-title":"Prurigo Nodularis: A review of IL-31RA blockade and other potential treatments","volume":"12","author":"Bewley","year":"2022","journal-title":"Dermatol Ther (Heidelb)."},{"key":"10.1016\/j.abd.2025.501210_bib0030","series-title":"Galderma Receives U.S. FDA Approval for Nemluvio\u00ae (Nemolizumab) for Adult Patients Living with Prurigo Nodularis [Internet]","year":"2024"},{"key":"10.1016\/j.abd.2025.501210_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40257-023-00818-z","article-title":"Chronic prurigo including prurigo nodularis: new insights and treatments","volume":"25","author":"M\u00fcller","year":"2024","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.abd.2025.501210_bib0040","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ad.2021.12.014","article-title":"Nemolizumab: an innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and prurigo nodularis","volume":"113","author":"Serra-Baldrich","year":"2022","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.abd.2025.501210_bib0045","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2025.501210_bib0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the Olympia 1 randomized clinical phase 3 trial","volume":"161","author":"St\u00e4nder","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2025.501210_bib0055","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jid.2023.12.003","article-title":"Comparing the efficacy of updated treatment choices for prurigo nodularis: a network meta-analysis","volume":"144","author":"Wang","year":"2024","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2025.501210_bib0060","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10787-024-01436-9","article-title":"A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis","volume":"32","author":"Nilforoushzadeh","year":"2024","journal-title":"Inflammopharmacology."},{"key":"10.1016\/j.abd.2025.501210_bib0065","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","article-title":"Nemolizumab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs."},{"key":"10.1016\/j.abd.2025.501210_bib0070","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/1744666X.2024.2306225","article-title":"A critical evaluation of nemolizumab for prurigo nodularis","volume":"20","author":"Brooks","year":"2024","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.abd.2025.501210_bib0075","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/bjd\/ljae207","article-title":"Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis","volume":"191","author":"Bahloul","year":"2024","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2025.501210_bib0080","series-title":"NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information [Internet]","year":"2024"},{"key":"10.1016\/j.abd.2025.501210_bib0085","series-title":"Nemluvio [Internet]","year":"2024"},{"key":"10.1016\/j.abd.2025.501210_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen","year":"2023","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.abd.2025.501210_bib0095","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.abd.2025.501210_bib0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.abd.2025.501210_bib0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2025.501210_bib0110","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.20873","article-title":"Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies","volume":"186","author":"Kabashima","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501210_bib0115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1529-8019.2008.00168.x","article-title":"Prurigo nodularis and lichen simplex chronicus","volume":"21","author":"Lotti","year":"2008","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2025.501210_bib0120","author":"Higgins"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625001527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625001527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:26:33Z","timestamp":1766186793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059625001527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0365059625001527"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2025.501210","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of nemolizumab in prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2025.501210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501210"}}